GW’s shares slump after NHS rejects cannabis drug over cost

A PIONEERING cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective.

 

 

 

Full Article:

http://www.cityam.com/1412816336/gw-s-shares-slump-after-nhs-rejects-cannabis-drug-over-cost

Post comment